Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Slides:

Advertisements

Similar presentations

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.

Advertisements

DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.

Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study by Cheng E. Chee, Aneel A. Ashrani,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

by Hugoline G. de Haan, Irene D. Bezemer, Carine J. M

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Central venous line–related thrombosis in children: association with central venous line location and insertion technique by Christoph Male, Peter Chait,

by Nadine Martel, James Lee, and Philip S. Wells

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use by Ida Martinelli, Anthonie W. A. Lensing, Saskia.

Recurrent thromboembolism in patients with vena cava filters

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Finding a diamond in the (mouse is) rough

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology by Mary Cushman,

A Systematic Review On Different Prothrombin Complex Concentrate Strategies To Reverse Vitamin K Antagonist Therapy by Nakisa Khorsand, Hilde A.M. Kooistra,

One giant leap for pediatric AMKL

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism by Sabine Eichinger, Verena Schönauer, Ansgar Weltermann,

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

by Alexander Röth, Andreas Hüttmann, Russell P

Learning Objectives Classification of VTE Goals of VTE Treatment.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

C-reactive protein and dialysis access

Primary testicular lymphoma

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia by Esperanza Such, Ulrich Germing, Luca Malcovati,

Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study Nicolas Faller, MD, PhD,

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk.

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Has MRD monitoring superseded other prognostic factors in adult ALL?

Incidence and Predictors Of Venous Thromboembolism Among Lymphoma Patients In Denmark: A Nationwide Population-Based Cohort Study by Jennifer L Lund, Lene.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients? Marie Méan, MD, Andreas Limacher, PhD,

C-reactive protein and dialysis access

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Symptomatic perioperative venous thromboembolism is a frequent complication in patients with a history of deep vein thrombosis Timothy K. Liem, MD, Thanh.

How I treat cancer-associated venous thromboembolism

Recurrent thromboembolism in patients with vena cava filters

by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study by Inger Lise Gade, Signe Juul Riddersholm, Ilse Christiansen,

Prevention of hospital-acquired thrombosis from a primary care perspective: a qualitative study by Ian Litchfield, David Fitzmaurice, Patricia Apenteng,

Baseline Characteristics of the Study Participants

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Rituximab immunotherapy: it’s getting personal

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Patient stratification using survival risk prediction and BCLC staging

A fishbone diagram summarising factors contributing to urology inpatients not having a 24-hour Electronic Patient Records venous thromboembolism (EPR VTE)

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Is Skull-Base to Proximal Thigh PET/CT Enough

Cold agglutinin disease

Presentation transcript:

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie Méan, Andreas Limacher, Nicolas Rodondi, and Drahomir Aujesky Blood Volume 126(16):1949-1951 October 15, 2015 ©2015 by American Society of Hematology

Kaplan–Meier curve for VTE recurrence in low- vs higher-risk patients. Kaplan–Meier curve for VTE recurrence in low- vs higher-risk patients. Low risk was defined as lowest quartile of predicted 12-month risk according to the updated Vienna Prediction Model. Tobias Tritschler et al. Blood 2015;126:1949-1951 ©2015 by American Society of Hematology